Use of Bevacizumab in Combination with Chemotherapy in Ovarian Cancer in a Community Practice Setting

Full Article

K Loh

Hong Kong J Radiol 2012;15(Suppl):S88-92

Although ovarian cancers tend to be fairly chemo-responsive initially, the difficulty facing clinicians is maintaining or prolonging the duration of disease control. In recent clinical trials, adding bevacizumab to standard chemotherapy and using bevacizumab in maintenance regimens has shown promising results in terms of improving progression-free survival in women with advanced ovarian cancer. In this report, four patients treated with bevacizumab in a community practice setting are presented to illustrate the typical clinical responses that may be achieved by incorporating this targeted agent into the treatment strategy.





雖然卵巢癌往往在起初階段對化療有反應,醫生所面對的困難卻是如何維持或延長疾病控制的時 間。最近的臨床試驗顯示在標準化療的過程中加入bevacizumab,以及在之後的維持療程當中使用 bevacizumab,都可以改善晚期卵巢癌患者的無進展存活期。本文報告在社區治療層面上在四名患者 的療程策略中加入bevacizumab之後的典型臨床反應。